As per the research report, the size of the Middle East and Africa Contrast Injector Market is valued at USD 66.48 million in 2023 and is projected to grow at a CAGR of 5.73%, reaching USD 87.82 million by 2028 during the forecast period 2023 to 2028.
The growing prevalence of cardiovascular and cancer diseases across the Middle East and Africa primarily drives the contrast injector market growth in the Middle East and Africa. Approximately 1.4 million people die each year due to cardiovascular diseases due to lifestyle changes, alcohol consumption, genetic issues, and lack of physical exercise. CT imaging, especially with the use of contrast injectors, plays a crucial role in cardiovascular scanning to detect issues in patients. The demand for contrast injector devices in the Middle East and African region is also rising in breast cancer cases, as contrast agents help detect tumor positions and spread.
Advancements in the development of contrast injectors that transition from manual to automated systems, rising demand for imaging procedures, the development of various types of contrast agents or contrast media for improved disease diagnosis and growing investments in research and development to enhance contrast injector technology propel the growth of the contrast injectors market in MEA. The rising support from public and private organizations in promoting advanced medical imaging solutions, favorable reimbursement policies for imaging procedures using contrast injectors, rising awareness among healthcare providers and patients about the benefits of contrast-enhanced imaging, technological innovations and integration of artificial intelligence (AI) in contrast injector devices and growing healthcare expenditure and infrastructure development in the region to support advanced medical technologies further fuel the growth rate of the MEA market.
The high cost of contrast injector devices is a major factor restraining the MEA market growth during the forecast period. Factors such as a shortage of skilled professionals, lack of awareness, manufacturing time, and raw material availability also hinder market growth. Additionally, the side effects of contrast agents, including allergies, pose challenges to the market.
This research report on the MEA Contrast Injector Market has been segmented and sub-segmented into the following categories.
The Middle East and Africa region held a moderate share of the global market in 2022. However, the MEA market is expected to grow steadily during the forecast period owing to the increasing investments in the healthcare sector and rising healthcare expenditure.
Saudi Arabia held a substantial share of the MEA market in 2022 and is predicted to grow at a healthy CAGR during the forecast period owing to the presence of well-established contrast injector companies and manufacturing facilities. Manufacturers are focusing on developing contrast media syringes, disposables, and injectors.
The contrast injectors market in UAE is expected to hold a considerable share of the MEA market during the forecast period. The growing number of laboratory and clinical trial centers, the presence of advanced infrastructure facilities and increasing efforts from the key market participants drive the UAE market growth.
KEY MARKET PLAYERS
The leading companies dominating the MEA Contrast Injector Market profiled in the report are Bracco Imaging S.p.A. (Italy), Bayer HealthCare (Germany), Sino Medical- Device Technology Co., Ltd. (China), VIVID IMAGING (China), GE Healthcare (U.S.), AngioDynamics (U.S.), Nemoto Kyorindo Co., Ltd. (Japan), Guerbet Group (France), Medtronic AG (Germany), Ulrich GmbH & Co. KG (Germany), and Apollo RT Co., Ltd. (China).,
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: firstname.lastname@example.org